Showing results (81-90 of 646) with videos related to

Sort By:
Pageof 65
Hemasphere|September 15, 2025
Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphomaNúria Martínez-Cibrián, Valentín Ortiz-Maldonado, Marta Español-Rego, et al.
Hemasphere|September 8, 2025
Outcome of patients with accelerated and blast-phase myeloproliferative neoplasms not eligible for intensive chemotherapy or allogeneic hematopoietic cell transplantation treated by azacitidine alone or in combination-A FIM studyCorentin Orvain, Suzanne Tavitian, Clémence Mediavilla, et al.
Hemasphere|July 29, 2025
Correction to "Quality of vitamin K antagonist treatment during the last year of life"
Hemasphere|July 8, 2025
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemiaElisa Lenti, Edoardo Visentin, Engin Bojnik, et al.
Hemasphere|July 29, 2025
Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patientsAnna Pia Enblad, Olga Krali, Henrik Gezelius, et al.
Hemasphere|July 14, 2025
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AMLDavid A Sallman, Rami S Komrokji, Amy E Dezern, et al.
Hemasphere|January 26, 2026
Blinatumomab in de novo AYA ALL-Results of the Australasian Leukaemia and Lymphoma Group ALL09 "SUBLIME" studyMatthew Greenwood, Shane Gangatharan, Michael Osborn, et al.
Hemasphere|December 25, 2025
MMS22L is a novel key actor of normal and pathological erythropoiesisElia Colin, Ivan Ferrer-Vicens, Dror Brook, et al.
Hemasphere|January 29, 2026
IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemiaRosita Del Prete, Vjola Tusha, Helga Simon-Molas, et al.
Hemasphere|December 10, 2025
Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapyLukas Scheller, Xiang Zhou, Henry Loeffler-Wirth, et al.
Pageof 65